Cancer Treatment: are treatments that may include surgery, chemotherapy, and radiation therapy. If your cancer is particularly sensitive to radiation therapy or chemotherapy, you may receive one of those therapies as your primary treatment. Adjuvant treatment.
ABSTRACT DATE: July 14, 2020 TIME: 7:00 am PDT, 10:00 am EDT This is the second topic in the webinar series on ‘ Predictive Genomics for Population & Personalized Health ’. C...
DATE: July 07, 2020 TIME: 9:00 am PDT The widely used TNM staging system is poorly predictive of response to adjuvant chemotherapy in Stage II and III colon cancer. As a result, there is ove...
DATE: June 30, 2020 TIME: 9:00am PDT, 12:00pm EDT QC laboratories perform a critical role in demonstrating pharmaceutical products are consistently manufactured, safe, potent, and pure. At t...
DATE: June 30, 2020 TIME: 8:00am PT, 11:00am Understanding the tumor microenvironment (TME) is essential for the development of effective treatments for cancer patients. Traditional multi...
DATE: June 18, 2020 TIME: 9:00am PDT, 12:00pm EDT Despite the success of immunotherapy against several malignancies including melanoma and lung adenocarcinoma, glioblastoma remains the excep...
COVID 19 has resulted in diverse research needs ranging from mechanism and impact of the disease, to solutions to identify, combat or treat the disease. Cellular technologies such as flow an...
Since the outbreak of the Covid-19 pandemic, the development of diagnostics for both the virus (molecular) and the host immune response (serological) has become essential for monitoring the...
Multiplex immunofluorescence IHC is a powerful technique to address the increasing research needs in immuno-oncology to better understand the tumor microenvironment. In this webinar, we will...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Neoantigen based personalized immuno-oncology drugs are a relatively new therapeutic avenue that have shown strong anti-tumor efficacy in the clinic. Neoantigen peptides have been widely rep...
While providing indispensable insight into immune processes, the live cell imaging of immune cells poses unique challenges due to their non-adherent nature. Suspension cells such as immune c...
Gene manipulation studies in primary human immune cells can answer important biological questions within a clinically relevant cellular context. In this webinar we explore the use of several...
Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understanding of cells and their surroundings by providin...
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
Immune checkpoint blockade has revolutionized the treatment for patients with cancer. Great efforts remain to better understand resistant mechanisms to treatment as well as means to improve...
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
Cancer initiation and virulence depends on mechanisms to evade host immunosurveillance and suppression of early invasion and growth. Distinct phenotypes of the immune infiltrates in and arou...
Cancer vaccines are increasingly being developed and tested as a cancer treatment and prevention strategy. Designing cancer vaccines is complicated by a number factors including choice of an...
Dr. Koenitzer will present an overview of her current research in immune suppression. After a brief introduction to the MILLIPLEX® multiplex immunoassay portfolio, Dr. Koenitzer will dis...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like...
One of the main challenges in cancer immunotherapy is the resistance to I-O therapies. Primary resistance can occur before treatment and acquired resistance can occur in patients who respond...
1. Identify 3 barriers to immune cell response to cancer 2. List 3 approaches to overcome immunosuppressive barriers to bolster the immune response to cancer 3. Explain how fusion proteins c...
ABSTRACT DATE: July 14, 2020 TIME: 7:00 am PDT, 10:00 am EDT This is the second topic in the webinar series on ‘ Predictive Genomics for Population & Personalized Health ’. C...
DATE: July 07, 2020 TIME: 9:00 am PDT The widely used TNM staging system is poorly predictive of response to adjuvant chemotherapy in Stage II and III colon cancer. As a result, there is ove...
DATE: June 30, 2020 TIME: 9:00am PDT, 12:00pm EDT QC laboratories perform a critical role in demonstrating pharmaceutical products are consistently manufactured, safe, potent, and pure. At t...
DATE: June 30, 2020 TIME: 8:00am PT, 11:00am Understanding the tumor microenvironment (TME) is essential for the development of effective treatments for cancer patients. Traditional multi...
DATE: June 18, 2020 TIME: 9:00am PDT, 12:00pm EDT Despite the success of immunotherapy against several malignancies including melanoma and lung adenocarcinoma, glioblastoma remains the excep...
COVID 19 has resulted in diverse research needs ranging from mechanism and impact of the disease, to solutions to identify, combat or treat the disease. Cellular technologies such as flow an...
Since the outbreak of the Covid-19 pandemic, the development of diagnostics for both the virus (molecular) and the host immune response (serological) has become essential for monitoring the...
Multiplex immunofluorescence IHC is a powerful technique to address the increasing research needs in immuno-oncology to better understand the tumor microenvironment. In this webinar, we will...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Neoantigen based personalized immuno-oncology drugs are a relatively new therapeutic avenue that have shown strong anti-tumor efficacy in the clinic. Neoantigen peptides have been widely rep...
While providing indispensable insight into immune processes, the live cell imaging of immune cells poses unique challenges due to their non-adherent nature. Suspension cells such as immune c...
Gene manipulation studies in primary human immune cells can answer important biological questions within a clinically relevant cellular context. In this webinar we explore the use of several...
Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understanding of cells and their surroundings by providin...
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
Immune checkpoint blockade has revolutionized the treatment for patients with cancer. Great efforts remain to better understand resistant mechanisms to treatment as well as means to improve...
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
Cancer initiation and virulence depends on mechanisms to evade host immunosurveillance and suppression of early invasion and growth. Distinct phenotypes of the immune infiltrates in and arou...
Cancer vaccines are increasingly being developed and tested as a cancer treatment and prevention strategy. Designing cancer vaccines is complicated by a number factors including choice of an...
Dr. Koenitzer will present an overview of her current research in immune suppression. After a brief introduction to the MILLIPLEX® multiplex immunoassay portfolio, Dr. Koenitzer will dis...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like...
One of the main challenges in cancer immunotherapy is the resistance to I-O therapies. Primary resistance can occur before treatment and acquired resistance can occur in patients who respond...
1. Identify 3 barriers to immune cell response to cancer 2. List 3 approaches to overcome immunosuppressive barriers to bolster the immune response to cancer 3. Explain how fusion proteins c...
Follow
